Navigation Links
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
Date:8/25/2009

resident of Research and Development at Amgen. "In contrast to a recent, smaller study of ESAs in a similar patient population, TREAT did not show a statistically significant adverse effect on all-cause mortality or cardiovascular morbidity when patients were treated to a hemoglobin target of 13 g/dL. We continue to believe that ESAs have a favorable benefit:risk profile when used according to the approved label."

Currently, Aranesp is indicated for the treatment of anemia in patients with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis. The approved label for Aranesp recommends individualizing dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL. TREAT studied uses for Aranesp in which it is not approved.

TREAT Study Design

TREAT was an international, Phase 3, randomized, double-blind, placebo-controlled study of 4,038 chronic kidney disease (CKD) patients with type-2 diabetes and anemia. It is the largest study of ESA use in CKD patients to date. Patients enrolled in the study were randomized in a one-to-one ratio to receive either treatment with Aranesp to a target hemoglobin of 13 g/dL or placebo. Due to the increased risk of negative outcomes associated with low hemoglobin levels, patients in the control arm whose hemoglobin fell below 9 g/dL were given Aranesp until their hemoglobin level was 9 g/dL. Investigators were blinded to this intervention.

TREAT had two primary endpoints. The first evaluated time to all-cause mortality or cardiovascular morbidity including heart attack (myocardial infarction), congestive heart failure, hospitalization for angina (myocardial ischemia), or stroke (cerebrovascular accident). The second primary endpoint evaluated time to all-cause mortality or chronic dialysis. TREAT was not designed to determine the appropriate hemoglobin target in this patient population.

For
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
2. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
3. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. Medarex to Receive Milestone Payment from Amgen
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent
10. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
11. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Bevacizumab Market ,2010-2019" ... under the trade name of Avastin, bevacizumab injection is ... 2010, it was approved by CFDA to treat metastatic ... China all come from Roche and its ...
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Bevacizumab Market 2015-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Genomic Health, Inc . (Nasdaq: GHDX ... Executive Chairman of the Board, will present at the Piper ... November 29, 2011 at 1:30 p.m. Eastern Time (ET).   ... of the presentation, visit the Investor Relations section of Genomic ...
... Nov. 22, 2011 Frost & Sullivan honors ... Sullivan 2011 North American Technology Innovation Award in ... VoXcell ® Imaging Suite.  For the first ... throughout the enterprise using robust industry-standard applications, leading-edge ...
Cached Medicine Technology:Genomic Health to Present at the Piper Jaffray Health Care Conference 2Genomic Health to Present at the Piper Jaffray Health Care Conference 3KJAYA Medical Honored with 2011 Frost & Sullivan Award for Technology Innovation in Web-based Medical Imaging Data Management 2
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and ... The American Heart Association hosts their well-known Heart Walk to raise money in awareness ... can be made. Walkers can participate in the cause and someone can also donate, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a ... struggling with chemical dependency, may be able to find some hope in the ... treatment center for addiction located in Western Michigan. Focusing on several different aspects ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Medical Solutions, ... 2015 Best Places to Work in Healthcare by Modern Healthcare and will ... , Now in its eighth year, the Best Places to Work in Healthcare ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ground ... the Food and Drug Administration to eliminate submental fat, also known as the double ... among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , Developed ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... is dedicated to distributing health information technology innovation to transform quality and efficiency ... of the survey will be de-identified and aggregated before being publicly shared to ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... Nov. 30 Mary Rita Hyland, Assistant Vice President of ... elected to the 2010 Board for the Workgroup for Electronic ... of leadership positions at SSI since joining the organization in ... of the Quality Assurance division and Business Continuity for SSI. ...
... of ,stroke belt, study finds , MONDAY, ... belt" of the southern United States have a lifelong higher ... live elsewhere later, a new study shows. , Data on ... South Carolina, Georgia, Tennessee, Arkansas, Mississippi and Alabama show a ...
... , LOS ANGELES, ... as a woman, and brings with it a host of uncomfortable ... mood swings, weight gain , night sweats and lethargy are ... worse, menopause signs and symptoms can show up a ...
... , ... , NEW YORK, Nov. 30 Distance runners who live at ... races in areas that are at sea level. Can heart failure ... tent-like, high-altitude simulator? , That is the question being studied among 15 heart ...
... Fla., Nov. 30 The launch of Invivo Corporation,s ... FDA-cleared, fully-automated morphological system for the detection and analysis ... system will be officially unveiled at the Radiological Society ... Developed in partnership with leading experts in breast MRI, ...
... safe transplant results in animals , MONDAY, Nov. 30 (HealthDay ... cells from transplanted human-derived umbilical cord blood could help treat ... that such stem cells can differentiate into a long list ... Soon Park of the Samsung Medical Center in Seoul, Korea, ...
Cached Medicine News:Health News:SSI Assistant Vice President Elected to WEDI Board 2Health News:Birth in South Raises Stroke Risk for Life 2Health News:Birth in South Raises Stroke Risk for Life 3Health News:Anti-Aging Institute of California Offers New Natural Solution for Menopause Symptoms 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 2Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 3Health News:Can Exposure to Low Oxygen Levels Benefit Heart Failure Patients? 4Health News:New Breast MRI Technology Enables Enhanced Breast Cancer Detection 2Health News:New Breast MRI Technology Enables Enhanced Breast Cancer Detection 3
Microcontroller-based isolated electrosurgical generator, designed for all general purpose surgical procedures. Unit includes: Instant Response technology, adaptive REM system, isolated output, CEM c...
Maddox rod and occluder...
Long handle occluder - White...
Double Ended Occluders...
Medicine Products: